Tonix Pharmaceuticals Announces the Isolation and Characterization of the (S)-Isomer of Tianeptine

TNX-4300’s Mechanism of Restoring Neuroplasticity Supports Development as a First-in-Class Oral Therapy for Depression, Bipolar Disorder, Alzheimer’s Disease and Parkinson’s Disease